Norcliffe Capital

Norcliffe Capital is a private investment firm specializing in tax-efficient investments within the life sciences and disruptive technology sectors. The firm focuses on early-stage investments in innovative companies, particularly in medical technology and biotechnology, aiming to support groundbreaking innovations that have the potential to transform lives and deliver meaningful returns. By connecting high-net-worth investors with pioneering medical technologies, Norcliffe Capital seeks to make a significant impact in the healthcare industry.

The firm's investment strategy emphasizes identifying and vetting innovations on the brink of breakthrough, ensuring that investments are uncorrelated to traditional markets and offer various exit routes with the potential for positive returns. Norcliffe Capital's portfolio includes companies like Afon Technology, which has developed a non-invasive blood glucose monitor, and Aureum Diagnostics, focusing on low-cost electrochemical biosensing platforms for medical diagnostics. These investments reflect the firm's commitment to supporting transformative technologies in the healthcare sector.

With decades of combined experience in the life sciences sectors, Norcliffe Capital provides more than just capital to its portfolio companies. The firm offers expertise, mentorship, and a network of connections to accelerate business performance and growth. By partnering with universities and co-investing with leading groups, Norcliffe Capital fosters a collaborative approach to innovation, ensuring that its investments not only achieve financial success but also contribute positively to society by addressing unmet medical needs and improving patient outcomes.